117 related articles for article (PubMed ID: 31490767)
41. In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C.
Kindler T; Breitenbuecher F; Kasper S; Stevens T; Carius B; Gschaidmeier H; Huber C; Fischer T
Leukemia; 2003 Jun; 17(6):999-1009. PubMed ID: 12764361
[TBL] [Abstract][Full Text] [Related]
42. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients.
Chai SK; Nichols GL; Rothman P
J Immunol; 1997 Nov; 159(10):4720-8. PubMed ID: 9366395
[TBL] [Abstract][Full Text] [Related]
43. [Inhibitors of JAK2/STAT Signaling Pathway and Hematologic Malignancies-Review].
Zhao YL; Liu GM; Zhang LJ; Liang WT; Cheng ZY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Aug; 24(4):1275-9. PubMed ID: 27531815
[TBL] [Abstract][Full Text] [Related]
44. Human leukemias with mutated FLT3 kinase are synergistically sensitive to FLT3 and Hsp90 inhibitors: the key role of the STAT5 signal transduction pathway.
Yao Q; Nishiuchi R; Kitamura T; Kersey JH
Leukemia; 2005 Sep; 19(9):1605-12. PubMed ID: 16034464
[TBL] [Abstract][Full Text] [Related]
45. Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.
Koblish H; Li YL; Shin N; Hall L; Wang Q; Wang K; Covington M; Marando C; Bowman K; Boer J; Burke K; Wynn R; Margulis A; Reuther GW; Lambert QT; Dostalik Roman V; Zhang K; Feng H; Xue CB; Diamond S; Hollis G; Yeleswaram S; Yao W; Huber R; Vaddi K; Scherle P
PLoS One; 2018; 13(6):e0199108. PubMed ID: 29927999
[TBL] [Abstract][Full Text] [Related]
46. ECPIRM, a Potential Therapeutic Agent for Cutaneous T-Cell Lymphoma, Inhibits Cell Proliferation and Promotes Apoptosis via a JAK/STAT Pathway.
Yang H; Ma P; Cao Y; Zhang M; Li L; Wei J; Tao L; Qian K
Anticancer Agents Med Chem; 2018; 18(3):401-411. PubMed ID: 28356009
[TBL] [Abstract][Full Text] [Related]
47. Fetal and neonatal hematopoietic progenitors are functionally and transcriptionally resistant to
Porter SN; Cluster AS; Yang W; Busken KA; Patel RM; Ryoo J; Magee JA
Elife; 2016 Nov; 5():. PubMed ID: 27879203
[TBL] [Abstract][Full Text] [Related]
48. Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis.
Nieborowska-Skorska M; Wasik MA; Slupianek A; Salomoni P; Kitamura T; Calabretta B; Skorski T
J Exp Med; 1999 Apr; 189(8):1229-42. PubMed ID: 10209040
[TBL] [Abstract][Full Text] [Related]
49. STAT signaling in the pathogenesis and treatment of leukemias.
Lin TS; Mahajan S; Frank DA
Oncogene; 2000 May; 19(21):2496-504. PubMed ID: 10851048
[TBL] [Abstract][Full Text] [Related]
50. STAT5 drives abnormal proliferation in autosomal dominant polycystic kidney disease.
Fragiadaki M; Lannoy M; Themanns M; Maurer B; Leonhard WN; Peters DJ; Moriggl R; Ong AC
Kidney Int; 2017 Mar; 91(3):575-586. PubMed ID: 28104302
[TBL] [Abstract][Full Text] [Related]
51. Src family kinases mediate cytoplasmic retention of activated STAT5 in BCR-ABL-positive cells.
Chatain N; Ziegler P; Fahrenkamp D; Jost E; Moriggl R; Schmitz-Van de Leur H; Müller-Newen G
Oncogene; 2013 Aug; 32(31):3587-97. PubMed ID: 22926520
[TBL] [Abstract][Full Text] [Related]
52. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
Rahmani M; Nguyen TK; Dent P; Grant S
Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
[TBL] [Abstract][Full Text] [Related]
53. Regulation of Stat5 by FAK and PAK1 in Oncogenic FLT3- and KIT-Driven Leukemogenesis.
Chatterjee A; Ghosh J; Ramdas B; Mali RS; Martin H; Kobayashi M; Vemula S; Canela VH; Waskow ER; Visconte V; Tiu RV; Smith CC; Shah N; Bunting KD; Boswell HS; Liu Y; Chan RJ; Kapur R
Cell Rep; 2014 Nov; 9(4):1333-48. PubMed ID: 25456130
[TBL] [Abstract][Full Text] [Related]
54. MUC1 in hematological malignancies.
Stroopinsky D; Kufe D; Avigan D
Leuk Lymphoma; 2016 Nov; 57(11):2489-98. PubMed ID: 27347699
[TBL] [Abstract][Full Text] [Related]
55. Imipramine blue sensitively and selectively targets FLT3-ITD positive acute myeloid leukemia cells.
Metts J; Bradley HL; Wang Z; Shah NP; Kapur R; Arbiser JL; Bunting KD
Sci Rep; 2017 Jun; 7(1):4447. PubMed ID: 28667329
[TBL] [Abstract][Full Text] [Related]
56. CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia.
Bertoli S; Boutzen H; David L; Larrue C; Vergez F; Fernandez-Vidal A; Yuan L; Hospital MA; Tamburini J; Demur C; Delabesse E; Saland E; Sarry JE; Galcera MO; Mansat-De Mas V; Didier C; Dozier C; Récher C; Manenti S
Oncotarget; 2015 Nov; 6(35):38061-78. PubMed ID: 26515730
[TBL] [Abstract][Full Text] [Related]
57. Stellettin B induces apoptosis in human chronic myeloid leukemia cells via targeting PI3K and Stat5.
Chen Y; Zhou Q; Zhang L; Zhong Y; Fan G; Zhang Z; Wang R; Jin M; Qiu Y; Kong D
Oncotarget; 2017 Apr; 8(17):28906-28921. PubMed ID: 28423649
[TBL] [Abstract][Full Text] [Related]
58. Apoptosis induced by molecular targeting therapy in hematological malignancies.
Adachi S; Leoni LM; Carson DA; Nakahata T
Acta Haematol; 2004; 111(1-2):107-23. PubMed ID: 14646349
[TBL] [Abstract][Full Text] [Related]
59. Constitutive activation of zebrafish Stat5 expands hematopoietic cell populations in vivo.
Lewis RS; Stephenson SE; Ward AC
Exp Hematol; 2006 Feb; 34(2):179-87. PubMed ID: 16459186
[TBL] [Abstract][Full Text] [Related]
60. Oncogenic STAT5 signaling promotes oxidative stress in chronic myeloid leukemia cells by repressing antioxidant defenses.
Bourgeais J; Ishac N; Medrzycki M; Brachet-Botineau M; Desbourdes L; Gouilleux-Gruart V; Pecnard E; Rouleux-Bonnin F; Gyan E; Domenech J; Mazurier F; Moriggl R; Bunting KD; Herault O; Gouilleux F
Oncotarget; 2017 Jun; 8(26):41876-41889. PubMed ID: 27566554
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
